New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:23 EDTGRFS, HALO, CRIS, ING, AMGN, SINA, EXAS, PRAN, MNKD, LULUOn The Fly: Pre-market Movers
HIGHER: Lululemon (LULU), up 3% following upgrade at Wedbush... SINA (SINA), up 3.5% after upgraded at Pacific Crest... Grifols (GRFS), up 2.5% after announcing 7-year agreement with Japanese Red Cross... Exact Sciences (EXAS), up 3.6% after Barron's says shares could rise 50%... Curis (CRIS), up 11% after announcing removal of FDA partial clinical hold on CUDC-427... Halozyme (HALO), up 9% after announcing that trial of Hylenex recombinant met primary endpoint... ING (ING), up 4.5% after paying EUR1.23B to Dutch State... Amgen (AMGN), up 2% after AMG 145 reduced LDL cholesterol in statin intolerant patients... LOWER: Prana (PRAN), down 66% after Alzheimer's study doesn't hit targets... MannKind (MNKD), down 5.6% after downgraded at Piper Jaffray.
News For LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
09:58 EDTSINASINA discloses resignation of EVP Chen
Subscribe for More Information
09:03 EDTAMGNAmgen treatment of ovarian cancer designated for orphan drug status
Subscribe for More Information
08:05 EDTEXASMDVIP announces Cologuard to be availble by perscription
Subscribe for More Information
07:35 EDTAMGNCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
05:58 EDTMNKDStocks with implied volatility movement; MNKD SHPG
Subscribe for More Information
04:57 EDTLULUlululemon partners with Dalai Lama Center
Subscribe for More Information
October 21, 2014
15:42 EDTAMGNAmgen issues statement regarding Third Point Investment
Amgen issued the following statement with respect to media inquiries concerning Third Point LLC's equity position in Amgen: "Amgen maintains an active, engaged dialogue with all shareholders. Amgen has always appreciated the perspectives of all of its shareholders, including Third Point, and welcomes constructive input toward our common goal of enhancing shareholder value. Amgen's Board of Directors frequently receives input from shareholders, including ideas like those offered by Third Point. The Board and management continually assess Amgen's strategic priorities and, when appropriate, take action to set the best path forward to increase shareholder value. Amgen's Board of Directors and management remain focused on addressing significant unmet medical needs for serious illnesses and driving value for all shareholders. We look forward to further updating our shareholders on Amgen's strategic priorities and update on our restructuring plans at our business review on October 28th."
14:25 EDTAMGNAmgen urged by Third Point to split up
In its Q3 investor letter, Dan Loeb's Third Point said it is now one of Amgen's (AMGN) largest shareholders. Amgen's first steps to target its "inflated cost structure" should be applauded, but Third Point believes "much more can and should be done," the firm wrote. Immediate action Amgen can take to create shareholder value include focusing its R&D efforts, providing long-term margin guidance demonstrating a commitment to reducing costs and creating clarity on additional shareholder returns, Third Point also said. Additionally, Third Point said it believes that Amgen could benefit from a separation and should seriously consider breaking up into a "MatureCo" and a "GrowthCo." Shares of Amgen are up 4% to $143.12 in afternoon trading following the circulation of Third Point's Q3 investor letter.
14:09 EDTAMGNThird Point discloses new positions in eBay, Alibaba, exit from Sony
In its Q3 investor letter, Third Point says it established a "significant" position in eBay (EBAY). Dan Loeb's hedge fund also revealed it has established a significant direct investment in Alibaba (BABA) shares now that the company is public. Third Point also said it is now one of Amgen's (AMGN) largest shareholders. During the quarter, Third Point exited its position in Sony (SNE) and reduced or exited other positions, including AIG (AIG), Hertz (HTZ) and Softbank (SFTBF), the firm stated in its letter. PRICE ACTION: Following the disclosures in the Third Point letter, Amgen is up 4%, eBay is up 2.3% and Alibaba is up 3.8%, while Sony shares trading in New York are down nearly 1%.
13:56 EDTAMGNDan Loeb discloses position in Amgen at Robin Hood Conference, CNBC reports
Subscribe for More Information
10:53 EDTEXASExact Sciences, Lumber Liquidators shorts recomended by Tilson, Bloomberg says
Kase Capital's Whitney Tilson recommended short positions in Exact Sciences (EXAS) and Lumber Liquidators (LL) while speaking at the Robin Hood Conference, according to Bloomberg.
08:18 EDTINGBasel Committee accelerating work on leverage ratio, FT says
The Basel Committee on Banking Supervision will begin work on the calibration of the leverage ratio, a measure of bank capital seen as less vulnerable to manipulation, sooner than previously planned, which suggests the finished rule could be released as soon as 2015 or 2016, which is ahead of the previous target date of 2017, reported Financial Times, citing comments from the secretary-general of the committee, William Coen. Publicly traded large U.S. banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Publicly traded large EU banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS). Reference Link
07:15 EDTAMGNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
12:36 EDTHALOOptions with decreasing implied volatility
Subscribe for More Information
09:04 EDTHALOBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
08:32 EDTHALOHalozyme receives FDA approval for new Hylenex recombinant facilities
Subscribe for More Information
07:19 EDTAMGNIBC Life Sciences to hold a conference
Subscribe for More Information
06:52 EDTMNKDMannKind initiated with a Neutral at Goldman
Target $6.
October 19, 2014
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
October 17, 2014
09:06 EDTAMGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use